Prof. dr. H. ten Cate
Position title: Professor, head Thrombosis Expertise Center, Maastricht University Medical Center and Cardiovascular Research Institute (CARIM), Maastricht
Education: University of Amsterdam, 1987, Medicine; 1987 Division of Hematology-Oncology, Beth Israel Hospital, Harvard Medical School, Boston, USA; Slotervaarthospital and Academic Medical Center (AMC), Amsterdam, 1996. Laboratory for Experimental Internal Medicine, AMC, 1996- 2002. Laboratory Clinical Thrombosis and Hemostasis, Maastricht University Medical center and Cardiovascular Research Institute Maastricht, 2002- Center for Clinical Thrombosis and Haemostasis, Gutenberg University Medical Center, Mainz
Positions and Employment: Professor in Internal medicine, vascular medicine specialist; head Thrombosis Expertise Center, Maastricht University Medical Center and Cardiovascular Research Institute (CARIM), Maastricht
Other Experience and Professional Memberships Chairman of the board, Dutch Federation of Anticoagulation clinics (FNT; 2011-), Fellow American Heart Foundation, Member American Society of Hematology. Editorial board: Journal of Thrombosis and Haemostasis, Academic Editor, PlosOne. Section editor Thrombosis and Haemostasis; Editor-in- chief (jointly with dr. Yukio Ozaki) Thrombosis Journal.
Honors: Clinical Established Investigatorship, Netherlands Heart Foundation (1996-2002); Gutenberg Research Fellow, Johannes Gutenberg University Mainz, Germany, 2013-2016.
Publications (total 320, as first author 31, as second last and last author 65 Hirsch index: total 61; 35 over last 10 years)
Best 10 selected peer-reviewed publications 1: Loeffen R, et al, Ten Cate H. The hypercoagulable profile of patients with stent thrombosis. Heart.2015 May 21. pii: heartjnl-2014-306685. 2: Hermanns MI, et al, Ten Cate H, Wild PS. Distribution, genetic and cardiovascular determinants of FVIII:c – Data from the population-based Gutenberg Health Study. Int J Cardiol. 2015 May 6;187:166-74. 3: Loeffen R, et al, ten Cate H, Lowe GD; on behalf of the PROSPER Study Group. Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study. J Gerontol A Biol Sci Med Sci. 2014 Dec 24. 4: Borissoff J, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011; May 5;364(18):1746-60. 5: Borissoff JI, et al, ten Cate H, Spronk HM. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010; 122(8):821-30. 6. Konings J, et al, ten Cate H, Ariens RA. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011;118(14):3942-51. Epub 2011 Aug 9. 7: Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women:results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation. 2010;122(18):1854-61.8: Loubele ST, et al, Spronk HM, ten Cate H. Activated protein C protects against myocardial ischemia/ reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol. 2009;29(7):1087-92.
Research Support (over the last 10 years) Ongoing Research Support CTMM (INCOAG) 1.045.000.Mechanisms of particulate matter induced thrombogenicity. – Thrombosis Expertise Center; Annadal foundation. CVON 2015: The role of hypercoagulability in atrial fibrillation (5.0 million euro in consortium). Completed Research Support The impact of coagulation factor XII on mechanisms of thrombosis in patients with cardiovascular disease (NHF). -Mechanisms of particulate matter induced thrombogenicity (NHF)-Working mechanisms of activated protein C in a mouse model for myocardial ischemia/reperfusion injury (Thrombosis Foundation).